Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared ... Medical & Regulatory Affairs at Novo Nordisk Inc. “We are pleased that the FDA has accepted our ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

This first-ever WHO endorsement of weight-loss treatments promises to boost Novo's attractiveness by increasing demand for semaglutide -- the GLP-1 receptor agonist the company markets as Zepbound ...

Novo Nordisk, a leading global healthcare company, announced that the US Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg ...

The manufacturer of semaglutide, Novo Nordisk, plans to seek U.S. Food and Drug Administration (FDA) approval for the drug to treat fatty liver disease later this year, researchers said.